4//SEC Filing
Clark Julie 4
Accession 0001209191-21-050750
CIK 0001501756other
Filed
Aug 9, 8:00 PM ET
Accepted
Aug 10, 9:26 PM ET
Size
6.2 KB
Accession
0001209191-21-050750
Insider Transaction Report
Form 4
Clark Julie
Chief Medical Officer
Transactions
- Award
Common Stock
2021-08-06+120,000→ 169,489 total
Footnotes (2)
- [F1]Reflects the grants of performance stock units, pursuant to which: (a) 1/3 of the shares will vest upon dosing of the first subject in a Phase 2 clinical trial of ADVM-022 in wet age-related macular degeneration; (b) 1/3 of the shares will vest upon dosing of the first subject in a potentially registrational clinical trial of ADVM-022 or another product candidate owned or being developed by Adverum in wet age-related macular degeneration or another indication determined by the Compensation Committee to represent a significant unmet medical need; and (c) 1/3 of the shares will vest upon consummation of a strategic corporate transaction, not constituting a change in control, that is determined by the Compensation Committee to be transformative for Adverum, in each case contingent upon certification by the Compensation Committee of the achievement of such milestone and subject to the Reporting Person's continued service with the Issuer on each such vesting date. See Footnote 2.
- [F2]Non-exclusive examples of a strategic corporate transaction are (i) a collaboration with another company for the development and commercialization of a major asset, (ii) a substantial royalty-based or other structured financing, and (iii) the acquisition or in-license of a significant asset for development and commercialization.
Documents
Issuer
Adverum Biotechnologies, Inc.
CIK 0001501756
Entity typeother
Related Parties
1- filerCIK 0001865738
Filing Metadata
- Form type
- 4
- Filed
- Aug 9, 8:00 PM ET
- Accepted
- Aug 10, 9:26 PM ET
- Size
- 6.2 KB